Evidence map›Paper›PMID 42749805›Full record

ArticleNature2026

Development of a random background to understand ligand optimization.

Xinyu Xu, Olivier Mailhot, Galen J Correy, Xi-Ping Huang, Joao M Braz, Da Shi, Karthik Srinivasan, Kara Zielinski, Yuliia Holota, Yuliia Kuziv and 22 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Xinyu Xu *Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Olivier Mailhot *Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Galen J Correy *Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Xi-Ping Huang *Department of Pharmacology, NIMH Psychoactive Drug Screening Program, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Joao M BrazDepartment of Anatomy, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8955-0735
Da ShiSchrödinger Inc., San Diego, CA, USA.ORCID http://orcid.org/0000-0002-1953-2299
Karthik SrinivasanDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Kara ZielinskiDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Yuliia HolotaEnamine Ltd., Kyiv, Ukraine.ORCID http://orcid.org/0009-0009-2329-7111
Yuliia KuzivEnamine Ltd., Kyiv, Ukraine.ORCID http://orcid.org/0000-0001-8005-8197
Christos Iliopoulos-TsoutsouvasCenter for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.
Nathan D LevinzonDepartment of Medicinal Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
Yagmur U DorukHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Moira M RachmanDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Morgan E DiolaitiHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5900-3060
Maisie G V StevensHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Fangyu LiuDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5022-0106
Katie L HollandDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Harald HübnerDepartment of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID http://orcid.org/0000-0002-7892-599X
Jing WangDepartment of Pharmacology, NIMH Psychoactive Drug Screening Program, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0009-0006-3929-9267
Yujin WuDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Alan AshworthHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-1446-7878
Alexandros MakriyannisCenter for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3272-3687
Yuqi ZhangSchrödinger Inc., San Diego, CA, USA.
Yurii S MorozEnamine Ltd., Kyiv, Ukraine.ORCID http://orcid.org/0000-0001-6073-002X
Peter GmeinerDepartment of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID http://orcid.org/0000-0002-4127-197X
Robert AbelSchrödinger Inc., New York, NY, USA.
Aashish ManglikDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-7173-3741
Allan I BasbaumDepartment of Anatomy, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-1710-6333
Bryan L RothDepartment of Pharmacology, NIMH Psychoactive Drug Screening Program, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. bryan_roth@med.unc.edu.ORCID http://orcid.org/0000-0002-0561-6520
James S FraserDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA. jaimefraser@gmail.com.ORCID http://orcid.org/0000-0002-5080-2859
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA. bshoichet@gmail.com.ORCID http://orcid.org/0000-0002-6098-7367

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ligand optimization is central to drug discovery, with hundreds of analogues often designed and synthesized between an initial hit and a therapeutic candidate

Identifiers

PMID42749805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.